Invivyd vs Protalix BioTherapeutics
Invivyd reported revenue of $53 million in fiscal 2025, about the same as Protalix BioTherapeutics' $53 million in fiscal 2025. Invivyd's revenue grew 110.5% in its latest year, and Protalix BioTherapeutics' fell 1.2%. Invivyd had an operating margin of -104.0%, against -10.4% at Protalix BioTherapeutics. Free cash flow was −$58 million at Invivyd and −$14 million at Protalix BioTherapeutics.
Side by side
| Invivyd | Protalix BioTherapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $53M | $53M |
| Revenue growth | 110.5% | −1.2% |
| Revenue growth a year, last 5 years | — | −3.5% |
| Gross margin | — | 48.8% |
| Operating margin | −104.0% | −10.4% |
| Net margin | −98.2% | −12.5% |
| Free cash flow | −$58M | −$14M |
| Free cash flow margin | −109.1% | −25.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 45.3% | −3.1% |
| Last close | $0.45 | $3.06 |
| P/E at the last close | — | 12.2× |
| Insider trades, last 12 months | sold $341,120 | bought $101,360, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
InvivydProtalix BioTherapeutics
Operating margin
Percent of revenue
InvivydProtalix BioTherapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
InvivydProtalix BioTherapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Invivyd and Protalix BioTherapeutics pages.